Existing users please login

Forgot Password

    Home / Markets / Industries / Health Care

    Thursday, November 19, 2009

    AstraZeneca Submits Brilinta NDA To FDA

    | Respond to Editor | Print

     
    By Sarah Turner
    MarketWatch Pulse
       

      LONDON -- Drugmaker AstraZeneca said Thursday that it has submitted a new drug application to the U.S. Food and Drug Administration for ticagrelor, an investigational oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndrome. The proposed trade name for ticagrelor is Brilinta.

      Copyright © 2009 MarketWatch, Inc.

      Fox Business Video


      Last 5 Stocks

      • Ticker
      • Company
      • Price
      • Change
       

      Personal Finance - Investing - Financial News - Business News - Stock Market Quotes & News - Small Business

      Advertise with us | Jobs at FOX Business Network | Internships at FBN

      Terms of use. Privacy Statement. For FOXBusiness.com technical issues write to foxbusinessonline@foxbusiness.com; for all other feedback, write to feedback@foxbusiness.com.

      Quotes delayed at least 15 minutes. Market Data provided by Interactive Data (Terms & Conditions). Powered and implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions.

      This material may not be published, broadcast, rewritten, or redistributed. ©2010 FOX News Network, LLC. All rights reserved.